Interestingly, the presence of PIK3CA mutations is associated with better treatment response to PI3K/AKT/mTOR pathway inhibitors, suggesting that this genetic alteration may serve as a marker for personalized medicine in order to predict treatment outcomes for this cancer entity [78,79]. Here, AKT1 is linked to cancer.